Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

An AAV-based bioluminescent reporter reveals dynamic YAP/TAZ-TEAD transcriptional activity during liver injury.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

Development and Validation of a Nomogram to Predict Liver Metastases in Patients With Gastric Cancer.

Indian journal of surgical oncology·2026
Same author

Peripheral nervous system involvement in Parkinson's disease: Peripheral neuropathy, neuromuscular junction dysfunction, and clinical implications.

Neuroscience and biobehavioral reviews·2026
Same author

One-Shot Pd(II)-Catalyzed Multiple C-H Activation Enables Modular Construction of Fluorenylidene Oxindole-Based Multi(Polycyclic) Aromatic Enes.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Development of flow cytometry bead-based opsonophagocytic assays to dissect cell-mediated functional antibody responses to malaria vaccines.

Malaria journal·2026
Same author

Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.

European journal of immunology·2026

相关实验视频

Updated: Jan 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K

通过选择性精确向疗法的局部补充抑制.

Haiyu Wang1, Daan J van den Brink1, Balthasar A Heesters2

  • 1Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.

Current opinion in immunology
|October 30, 2025
PubMed
概括

向补充抑制剂为治疗因过度补充激活引起的疾病提供了一个有希望的新策略. 与系统方法相比,局部抑制可以降低风险和成本.

更多相关视频

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

相关实验视频

Last Updated: Jan 12, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

4.3K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.3K

科学领域:

  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 过度的补充激活是许多严重的人类疾病的关键因素.
  • 目前的补充抑制剂通常是系统的,导致高成本和增加感染风险.

研究的目的:

  • 审查局部补充抑制的新策略.
  • 专注于使用抗体技术针对特定组织的向,以抑制补充剂.

主要方法:

  • 对局部补剂抑制的临床前和临床开发方法的审查.
  • 专注于基于抗体的组织特定向策略.

主要成果:

  • 局部补充抑制提供了降低剂量,降低成本和提高安全性概况的潜力.
  • 通过抗体技术针对特定组织是开发的一个关键领域.

结论:

  • 向补充抑制剂对选择性抑制疾病部位具有显著的前景.
  • 即将推出的疗法旨在减轻与全身补剂抑制相关的风险.